The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Giredestrant shows promise despite missing primary goal
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Germany will be the first launch market
Subscribe To Our Newsletter & Stay Updated
